Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Tailor-made Pharma Solutions

Make better informed business decisions with customized pharmaceutical consulting and marketing services that give you the edge over your competition.

Tailor-made solutions

Use the expertise and experience of Pharma Intelligence to produce custom solutions that are actionable, flexible, and tailored to help you successfully navigate biopharma portfolio management, commercial optimization, and R&D strategy. Benefit from:

A customized approach – we develop solutions to fit your situation
Joint problem/opportunity definition
Proprietary data and complementary market research
The experience of 500+ industry experts
Collaborative problem solving
Fact-based decisions and actionable recommendations
Ownership of final decisions and action plans

Discover new business opportunities, reduce risks, and make better, faster decisions with tailor-made pharmaceutical solutions from Pharma Intelligence.

Scrip

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

By Brian Yang 18 Oct 2019

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.

Topic Deal trends Strategy

View article
Scrip

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 18 Oct 2019

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic Cancer Drug development landscape Research

View article
Scrip

Woodford Debacle Is A Test Of UK Biotech's Resilience

By Andrew McConaghie 18 Oct 2019

Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

Topic BioPharmaceutical Company analysis

View article
Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 18 Oct 2019

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell and gene therapy Drug development landscape

View article
Scrip

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

By Andrew McConaghie 18 Oct 2019

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.

Topic Research BioPharmaceutical

View article
Scrip

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

By Mandy Jackson 18 Oct 2019

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

View article
Biomedtracker, Meddevicetracker

Q4 2019 Outlook Report Extract

16 Oct 2019

What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.

Topic Clinical trials Drug development landscape

Single report
Meddevicetracker

Q3 2019 Catalyst Roundup

16 Oct 2019

What were the outcomes of critical catalysts featured in Meddevicetracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

Topic Drug approval

View infographic
Biomedtracker

Q3 2019 Catalyst Roundup

16 Oct 2019

What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

Topic Drug approval Drug review FDA

View infographic
Pink Sheet

Pink Sheet Sample Article Pack: The Hottest Topics in Pharma Regulatory Compliance

16 Oct 2019

When you look at newly approved drugs, the latest product reviews and the decisions made during the process, you can gain critical insights to inform your own strategic decisions. That’s what Pink Sheet delivers, and now you can try it for free.

Topic Drug approval Drug development landscape

View article
Pink Sheet

Pink Sheet Performance Trackers: Navigate a complex world with the regulatory performance trackers from Pink Sheet

16 Oct 2019

Keep track of compliance, legislation, policy regulations, and industry developments with the expertise of our worldwide network of expert analysts and journalists on the ground in key global regions.

Topic Drug development landscape Drug review FDA

View article
Scrip

Opioids Crisis Commercial Implications for an Embattled Industry

14 Oct 2019

Find out how the consequences of the opioids crisis is affecting the pharma industry, from shaping the way deals are made, to transforming the development of new categories of drugs. Scrip brings you the implications behind the headlines in an essential free article pack.

Topic Drug development landscape FDA

View article
Pink Sheet

The Opioids Crisis Regulatory Response to an Epidemic

14 Oct 2019

With the opioid crisis in full swing in the US, government and regulatory agencies are announcing changes to guidance and legislation related to both new and existing drugs. Keep abreast of these critical changes with essential coverage from Pink Sheet.

Topic Drug approval FDA

View article
Trialtrove

Trialtrove 2018 Clinical Trials Roundup Surveying the Landscape of 2018 Trial Starts infographic

11 Oct 2019

A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.

Topic Drug development landscape BioPharmaceutical Business strategies

View article
Trialtrove

2018 Clinical Trials Roundup: Surveying the Landscape of 2018 Trial Starts

11 Oct 2019

See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.

Topic Drug development landscape BioPharmaceutical Business strategies

View article

Latest headlines

Pink Sheet

18 Oct 2019

Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation

Link
Scrip

18 Oct 2019

Novartis Q3 Preview: Zolgensma Back In The Spotlight

Link
Medtech Insight

18 Oct 2019

QUOTED. 18 October 2019. CJ Porter.

Link
Pink Sheet

18 Oct 2019

ANDA Reviews Sometimes Miss GDUFA Goal Dates To Get Quicker Approval, But How Often?

Link
Pink Sheet

18 Oct 2019

Top US FDA Officials Continue To Lament Advisory Cmte. Recruitment Difficulties

Link
Pink Sheet

17 Oct 2019

Reprieve For Life Sciences As Brexit Deal Approved

Link
Medtech Insight

17 Oct 2019

Compliance Corner: Cybersecurity Patches Aren't Recall Events – But A New 510(k) May Be Needed Over Time, Expert Says

Link
Scrip

17 Oct 2019

AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing

Link
Pink Sheet

17 Oct 2019

Italy: Added Benefit Will Be Key To Reimbursement

Link
Scrip

17 Oct 2019

Need For Partnering Won’t Change But Shape Might - BioJapan

Link
Pink Sheet

17 Oct 2019

UCB Pharma Among Latest Sponsors Up For CHMP Oral Explanations

Link
Medtech Insight

17 Oct 2019

Graeme Tunbridge To Lead MHRA Devices Unit During Interim, Reports Indicate

Link
Scrip

17 Oct 2019

Teva's Opioid Options Come Into More Focus Ahead Of Third Quarter Financials

Link
Medtech Insight

17 Oct 2019

Device Week, 17 October 2019 – A Mix Of Earnings and "Taboo" Tech: Johnson & Johnson's Third-Quarter Earnings; Tech Innovations Around Sex And Death

Link
Pink Sheet

17 Oct 2019

US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Tailor-made Pharma Solutions

Tailor-made solutions

Pharma Intelligence latest insights

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

Woodford Debacle Is A Test Of UK Biotech's Resilience

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

Q4 2019 Outlook Report Extract

Q3 2019 Catalyst Roundup

Q3 2019 Catalyst Roundup

Pink Sheet Sample Article Pack: The Hottest Topics in Pharma Regulatory Compliance

Pink Sheet Performance Trackers: Navigate a complex world with the regulatory performance trackers from Pink Sheet

Opioids Crisis Commercial Implications for an Embattled Industry

The Opioids Crisis Regulatory Response to an Epidemic

Trialtrove 2018 Clinical Trials Roundup Surveying the Landscape of 2018 Trial Starts infographic

2018 Clinical Trials Roundup: Surveying the Landscape of 2018 Trial Starts

Latest headlines

Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation

Novartis Q3 Preview: Zolgensma Back In The Spotlight

QUOTED. 18 October 2019. CJ Porter.

ANDA Reviews Sometimes Miss GDUFA Goal Dates To Get Quicker Approval, But How Often?

Top US FDA Officials Continue To Lament Advisory Cmte. Recruitment Difficulties

Reprieve For Life Sciences As Brexit Deal Approved

Compliance Corner: Cybersecurity Patches Aren't Recall Events – But A New 510(k) May Be Needed Over Time, Expert Says

AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing

Italy: Added Benefit Will Be Key To Reimbursement

Need For Partnering Won’t Change But Shape Might - BioJapan

UCB Pharma Among Latest Sponsors Up For CHMP Oral Explanations

Graeme Tunbridge To Lead MHRA Devices Unit During Interim, Reports Indicate

Teva's Opioid Options Come Into More Focus Ahead Of Third Quarter Financials

Device Week, 17 October 2019 – A Mix Of Earnings and "Taboo" Tech: Johnson & Johnson's Third-Quarter Earnings; Tech Innovations Around Sex And Death

US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store